# ë°°ê²½ ìë£Œ: PL1 Legionella ë…ì„± ì¸ìì˜ ADP-Ribosylationê³¼ Ubiquitination

**ë°œí‘œ**: PL1 - Plenary Lecture 1
**ì¼ì‹œ**: 2025ë…„ 10ì›” 26ì¼ (ì¼) 15:40-16:20
**ì¥ì†Œ**: Convention Hall 1
**ì¢Œì¥**: You-Hee Cho (CHA University)
**ì¤‘ìš”ë„**: â­â­â­â­â­ (95/100ì ) - **Plenary Lecture! ëª¨ë“  ì°¸ê°€ì í•„ìˆ˜**

---

## ğŸ¯ ë°œí‘œ ê°œìš”

**ì—°ì‚¬**: Zhao-Qing Luo (ç½—æ˜­åº†)
**ì†Œì†**: The First Hospital of Jilin University, P. R. China (ì¤‘êµ­ ì§€ë¦°ëŒ€í•™êµ ì œ1ë³‘ì›)
**ì œëª©**: ADP-Ribosylation, ubiquitination and beyond by Legionella virulence factors

### ì™œ ì´ ë°œí‘œê°€ ì¤‘ìš”í•œê°€?

- ğŸ† **Plenary Lecture**: MSK2025ì˜ ìµœê³  ìˆ˜ì¤€ ë°œí‘œ ì¤‘ í•˜ë‚˜
- ğŸ”¬ **ìµœì‹  ì—°êµ¬ ë™í–¥**: 2024ë…„ Nature Communications 2í¸ ê²Œì¬ (3ì›”, 7ì›”)
- ğŸ§¬ **ìƒˆë¡œìš´ PTM ë©”ì»¤ë‹ˆì¦˜**: Bacteriaê°€ host ubiquitinationì„ ì¡°ì‘í•˜ëŠ” ë…íŠ¹í•œ ë°©ë²•
- ğŸ’¡ **ADP-ribosylation ì „ë¬¸ê°€**: Luo êµìˆ˜ëŠ” ì´ ë¶„ì•¼ì˜ ì„¸ê³„ì  ê¶Œìœ„ì
- ğŸ… **2025 Biochemical Society Award** ìˆ˜ìƒì

### ë© êµ¬ì„±ì›ë“¤ì—ê²Œ ìœ ìš©í•œ ì´ìœ 

**ì„¸ê·  ë³‘ì›ì„± ì—°êµ¬ì**:
- Legionella effectorì˜ host cell hijacking ë©”ì»¤ë‹ˆì¦˜
- Type IV secretion system (T4SS)ì˜ ì—­í• 
- Intracellular bacteriaì˜ ìƒì¡´ ì „ëµ

**Post-translational modification (PTM) ì—°êµ¬ì**:
- ë…íŠ¹í•œ ADP-ribosylation ë©”ì»¤ë‹ˆì¦˜ (PR-Ub, ADP-ribosylated Ub)
- Ubiquitinationì˜ ë¹„ì •ìƒì  ë³€í˜•
- Metaeffector (MavL)ì˜ ì—­ì¡°ì ˆ ë©”ì»¤ë‹ˆì¦˜

**ì„¸í¬ ìƒë¬¼í•™ ì—°êµ¬ì**:
- Ubiquitin homeostasis ìœ ì§€ ë©”ì»¤ë‹ˆì¦˜
- Bacterial effectorsì˜ ì„¸í¬ ë‚´ ê¸°ëŠ¥
- Host-pathogen interactionì˜ ë¶„ì ë©”ì»¤ë‹ˆì¦˜

---

## ğŸ“‹ ì—°ì‚¬ ë°°ê²½ ë° ìµœê·¼ ì—°êµ¬

### Zhao-Qing Luo êµìˆ˜ ì†Œê°œ

**í˜„ì¬ ì†Œì†**:
- The First Hospital of Jilin University, China (2024~í˜„ì¬)
- ì´ì „: Purdue University, Department of Biological Sciences (ë¯¸êµ­)

**ì£¼ìš” ì—°êµ¬ ë¶„ì•¼**:
- Legionella pneumophila ë³‘ì›ì„± ë©”ì»¤ë‹ˆì¦˜
- Bacterial effector proteinì˜ host cell ì¡°ì‘
- ADP-ribosylationê³¼ ubiquitinationì˜ crosstalk

**ìµœê·¼ ìˆ˜ìƒ**:
- **2025**: Biochemical Society Award for Significant Breakthrough or Achievement

### ìµœê·¼ ì£¼ìš” ì—°êµ¬ ì„±ê³¼ (2024)

#### 1. Nature Communications (July 2024) - Ubiquitin Homeostasis

**ë…¼ë¬¸ ì œëª©**: "Legionella maintains host cell ubiquitin homeostasis by effectors with unique catalytic mechanisms"

**í•µì‹¬ ë°œê²¬**:
```
SidE effector â†’ PR-Ub (phosphoribosyl ubiquitin) ìƒì„±
         â†“
LnaB effector â†’ ADP-ribosylated Ub ì „í™˜
         â†“
MavL (ADP-ribosyl)hydrolase â†’ ADP-ribose + Functional Ub
         â†“
Ubiquitin pool ìœ ì§€ (Homeostasis)
```

**í˜ì‹ ì„±**:
- Legionellaê°€ ìˆ™ì£¼ ubiquitinì„ ë³€í˜•í•˜ë©´ì„œë„ ê³ ê°ˆì‹œí‚¤ì§€ ì•ŠëŠ” ë©”ì»¤ë‹ˆì¦˜ ê·œëª…
- **3ë‹¨ê³„ effector cascade**: SidE â†’ LnaB â†’ MavL
- Ub homeostasis ì—†ì´ëŠ” ê°ì—¼ ì„¸í¬ê°€ ì‚¬ë©¸ â†’ ì„¸ê· ë„ ì£½ìŒ

#### 2. Nature Communications (March 2024) - MavL Metaeffector

**ë…¼ë¬¸ ì œëª©**: "Legionella metaeffector MavL reverses ubiquitin ADP-ribosylation via a conserved arginine-specific macrodomain"

**í•µì‹¬ ë°œê²¬**:
- MavLì€ **metaeffector** (ë‹¤ë¥¸ effectorë¥¼ ì¡°ì ˆí•˜ëŠ” effector)
- Ubiquitinì˜ **Arginine 42**ì— ë¶™ì€ ADP-ribosylationì„ ì œê±°
- **Macrodomain** êµ¬ì¡° ì´ìš© (Arg-specific ADP-ribosylhydrolase)

**ìƒë¬¼í•™ì  ì˜ë¯¸**:
- Modified ubiquitinì˜ ë…ì„± íš¨ê³¼ ìµœì†Œí™”
- ìˆ™ì£¼ ì„¸í¬ ìƒì¡´ ì—°ì¥ â†’ Legionella ì¦ì‹ ì‹œê°„ í™•ë³´
- SidE familyì™€ MavLì˜ ê· í˜•ì´ ê°ì—¼ ì„±ê³µì˜ í•µì‹¬

---

## ğŸ”¬ ë°œí‘œ ì˜ˆìƒ ë‚´ìš©

### 1. Legionella pneumophila ì†Œê°œ

**ê°ì—¼ ê²½ë¡œ ë° ì§ˆë³‘**:
- **ë³‘ëª…**: Legionnaires' disease (ì¬í–¥êµ°ì¸ë³‘), Pontiac fever
- **ê°ì—¼ì›**: ì—ì–´ë¡œì¡¸ í¡ì… (ëƒ‰ê°íƒ‘, ìƒ¤ì›Œê¸°, ë¶„ìˆ˜)
- **ì„¸í¬ ë‚´ ê¸°ìƒ**: Alveolar macrophage ë‚´ì—ì„œ ì¦ì‹
- **ì¦ìƒ**: íë ´, ë°œì—´, ê·¼ìœ¡í†µ (ì¹˜ì‚¬ìœ¨ 10-15%)

**ë…íŠ¹í•œ ìƒì¡´ ì „ëµ**:
```
1. Amoebaì™€ ê³µìƒ ì§„í™”
   â†’ ì›ìƒë™ë¬¼ ë‚´ ìƒì¡´ ëŠ¥ë ¥ íšë“
   â†’ ì¸ê°„ macrophageë„ ì‰½ê²Œ ê°ì—¼

2. Legionella-containing vacuole (LCV) í˜•ì„±
   â†’ Lysosome ìœµí•© íšŒí”¼
   â†’ ERê³¼ ìœ ì‚¬í•œ í™˜ê²½ ì¡°ì„±

3. 300ê°œ ì´ìƒì˜ effector protein ë¶„ë¹„
   â†’ T4SS (Type IV Secretion System) ì´ìš©
   â†’ Host cell ì „ë°©ìœ„ ì¡°ì‘
```

### 2. SidE Family: ë…íŠ¹í•œ Ubiquitination ì‹œìŠ¤í…œ

**ì „í†µì  Ubiquitination vs. SidE-mediated Ubiquitination**:

```yaml
ì „í†µì  ë°©ë²• (E1-E2-E3 cascade):
  E1: Ubiquitin activation (ATP ì†Œëª¨)
  E2: Ubiquitin conjugation
  E3: Substrate recognition
  ê²°ê³¼: Lysineì— isopeptide bond

SidE ë°©ë²• (E1/E2/E3 ë¶ˆí•„ìš”!):
  SidE: Ubì˜ C-ë§ë‹¨ì„ ADP-ribosylation
       â†’ PR-Ub (phosphoribosyl-Ub)
       â†’ Substrateì˜ Serineì— PR-Ub ê²°í•©
  ê²°ê³¼: Serine esterification (ê°€ì—­ì !)
```

**SidE Family êµ¬ì„±ì›**:
- **SdeA, SdeB, SdeC, SidE** (4ê°œ paralog)
- ëª¨ë‘ ë™ì¼í•œ PDE (phosphodiesterase) domain ë³´ìœ 
- Hostì˜ Rab33b, Rab1, Rab10 ë“±ì„ ubiquitinate

**ìƒë¬¼í•™ì  ê²°ê³¼**:
- ER-to-Golgi trafficking ì°¨ë‹¨
- Vesicle transport êµë€
- LCVì— ER ë‹¨ë°±ì§ˆ ë™ì›

### 3. LnaB: PR-Ubë¥¼ ADP-ribosylated Ubë¡œ ì „í™˜

**LnaBì˜ ê¸°ëŠ¥** (2024ë…„ 7ì›” Nature Comm. ë°œê²¬):

```
PR-Ub (phosphoribosyl-ubiquitin)
         â†“ LnaB
ADP-ribosylated Ub
```

**ë©”ì»¤ë‹ˆì¦˜**:
- LnaBëŠ” **glycohydrolase** í™œì„± ë³´ìœ 
- PR-Ubì˜ phosphoribose-Ub bond ì ˆë‹¨
- ìƒˆë¡œìš´ ADP-ribose-Ub í˜•ì„±

**ì™œ ì´ ë‹¨ê³„ê°€ í•„ìš”í•œê°€?**:
- PR-UbëŠ” ë¶ˆì•ˆì • â†’ ì¶•ì ë˜ë©´ ë…ì„±
- ADP-ribosylated UbëŠ” MavLì˜ ê¸°ì§ˆë¡œ ì‚¬ìš©
- Effector cascadeì˜ ì¤‘ê°„ ë‹¨ê³„

### 4. MavL Metaeffector: Ub Homeostasisì˜ í•µì‹¬

**MavLì˜ êµ¬ì¡°ì™€ ê¸°ëŠ¥**:

**ë„ë©”ì¸ êµ¬ì¡°**:
```
[N-terminal] - [Macrodomain] - [C-terminal]
                    â†‘
              ADP-ribosylhydrolase
              (Arg-specific)
```

**íš¨ì†Œ ë°˜ì‘**:
```
ADP-ribosylated Ub (on Arg42)
         â†“ MavL macrodomain
ADP-ribose + Functional Ub (ë³µì›!)
```

**Arginine 42ì˜ ì¤‘ìš”ì„±**:
- Ubiquitinì˜ critical residue
- E1 enzymeê³¼ì˜ interactionì— í•„ìˆ˜
- ADP-ribosylation â†’ Ub ê¸°ëŠ¥ ìƒì‹¤
- MavL â†’ Ub ê¸°ëŠ¥ ë³µì›

**Metaeffectorë¡œì„œì˜ ì—­í• **:
```yaml
Positive regulation (SidE, LnaB):
  â†’ Host ubiquitination ì¡°ì‘
  â†’ LCV í˜•ì„± ì´‰ì§„

Negative regulation (MavL):
  â†’ Modified Ub ì œê±°
  â†’ Ub pool ê³ ê°ˆ ë°©ì§€
  â†’ ìˆ™ì£¼ ì„¸í¬ ìƒì¡´ ì—°ì¥
```

### 5. Ubiquitin Homeostasis: ê· í˜•ì˜ ì˜ˆìˆ 

**ë¬¸ì œ ìƒí™©**:
- SidE familyê°€ ê³„ì† Ubë¥¼ ë³€í˜• â†’ Ub pool ê³ ê°ˆ
- Modified Ub ì¶•ì  â†’ ë…ì„± íš¨ê³¼ â†’ ìˆ™ì£¼ ì„¸í¬ ì‚¬ë©¸
- ìˆ™ì£¼ ì£½ìŒ â†’ Legionellaë„ ì¦ì‹ ëª»í•¨

**í•´ê²°ì±…: 3-Effector System**:

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ SidE: PR-Ub ìƒì„± (Ub ì†Œëª¨)          â”‚
â”‚   â†“                                  â”‚
â”‚ LnaB: ADP-ribosylated Ub ì „í™˜       â”‚
â”‚   â†“                                  â”‚
â”‚ MavL: Ub ë³µì› (Ub ì¬ìƒ)            â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
     â†’ Closed cycle!
```

**ì •ëŸ‰ì  ê· í˜•**:
- SidE/LnaB í™œì„± > MavL â†’ LCV í˜•ì„± ì´‰ì§„ (ê°ì—¼ ì´ˆê¸°)
- MavL í™œì„± ì¦ê°€ â†’ Ub homeostasis (ê°ì—¼ ì¤‘í›„ê¸°)
- ì‹œê°„ì— ë”°ë¥¸ effector ë°œí˜„ëŸ‰ ì¡°ì ˆ ì¤‘ìš”

### 6. ì¹˜ë£Œì œ ê°œë°œ ê°€ëŠ¥ì„±

**íƒ€ê²Ÿ ì„ ì •**:

**Option 1: SidE ì–µì œ**
- PR-Ub ìƒì„± ì°¨ë‹¨
- ì¥ì : LCV í˜•ì„± ì–µì œ
- ë‹¨ì : 4ê°œ paralog ëª¨ë‘ ì–µì œ í•„ìš”

**Option 2: MavL ì–µì œ**
- Ub homeostasis íŒŒê´´
- ì¥ì : ìˆ™ì£¼ ì„¸í¬ ì‚¬ë©¸ ìœ ë„ â†’ Legionella ë°©ì¶œ â†’ ë©´ì—­ ì œê±°
- ë‹¨ì : ìˆ™ì£¼ ì„¸í¬ ì†ìƒ

**Option 3: LnaB ì–µì œ**
- Cascade ì¤‘ë‹¨
- ì¥ì : PR-Ub ì¶•ì  â†’ ë…ì„±
- ë‹¨ì : ìƒˆë¡œìš´ íƒ€ê²Ÿ, ì–µì œì œ ê°œë°œ í•„ìš”

**High-throughput screening (HTS)**:
- 2025ë…„ ChemBioChem ë…¼ë¬¸: SdeA ì–µì œì œ ìŠ¤í¬ë¦¬ë‹ assay ê°œë°œ
- Small molecule library íƒìƒ‰ ì§„í–‰ ì¤‘

---

## ğŸ“ ë°°ê²½ ì§€ì‹

### ADP-Ribosylationì´ë€?

**ì •ì˜**:
- NAD+ì˜ ADP-riboseë¥¼ ë‹¨ë°±ì§ˆì— ì „ë‹¬í•˜ëŠ” post-translational modification
- ë‹¨ë°±ì§ˆì˜ arginine, asparagine, cysteine, serine ë“±ì— ë¶€ì°©

**ì¢…ë¥˜**:
```
Mono-ADP-ribosylation (MARylation):
  â†’ 1ê°œì˜ ADP-ribose ë¶€ì°©
  â†’ Legionella effectors, Cholera toxin ë“±

Poly-ADP-ribosylation (PARylation):
  â†’ ADP-ribose chain í˜•ì„±
  â†’ PARP family (DNA damage response)
```

**Legionellaì˜ ADP-ribosyltransferases**:
- RalF: Arf1 GTPaseë¥¼ ADP-ribosylate
- AnkX: Rab1, Rab35 phosphocholination (ë³€í˜•ëœ ADP-ribosylation)
- SidE family: Ubiquitin ADP-ribosylation (ë…íŠ¹!)

### Macrodomainì´ë€?

**êµ¬ì¡°**:
- ~180 amino acid domain
- ADP-ribose ê²°í•©/ì œê±° ê¸°ëŠ¥
- Î±/Î²/Î± sandwich fold

**ê¸°ëŠ¥**:
```
1. ADP-ribose reader:
   â†’ Protein-ADP-ribose ì¸ì‹

2. ADP-ribosylhydrolase:
   â†’ ADP-ribose ì œê±° (de-ADP-ribosylation)
   â†’ MavLì´ ì´ ê¸°ëŠ¥ ë³´ìœ !

3. Poly-ADP-ribose binding:
   â†’ PARP signaling ì¡°ì ˆ
```

**MavL macrodomainì˜ íŠ¹ì´ì„±**:
- **Arginine-specific**: Argì— ë¶™ì€ ADP-riboseë§Œ ì œê±°
- **Ubiquitin-specific**: Ubì˜ Arg42ë§Œ ì¸ì‹
- ë‹¤ë¥¸ macrodomainì€ Ser/Asp ADP-ribose ì œê±°

### Type IV Secretion System (T4SS)

**êµ¬ì¡°**:
```
Bacterial cytoplasm
         â†“
   T4SS complex
   (Dot/Icm system - 27 proteins!)
         â†“
Inner membrane â†’ Periplasm â†’ Outer membrane
         â†“
Host cell cytoplasm
```

**Legionella Dot/Icm T4SSì˜ íŠ¹ì§•**:
- **300ê°œ ì´ìƒì˜ effector** ë¶„ë¹„ (ì„¸ê·  ì¤‘ ìµœë‹¤!)
- Contact-dependent injection
- Translocation signal: C-terminal 20-30 aa

**ì£¼ìš” effector ì¹´í…Œê³ ë¦¬**:
```yaml
Vesicle trafficking:
  - RalF, LidA, SidM/DrrA (Rab1 ì¡°ì‘)
  - SidC, SdcA (ER recruitment)

Ubiquitination:
  - SidE family (PR-Ub)
  - LnaB, MavL (Ub homeostasis)

Apoptosis inhibition:
  - SdhA, SidF
  - Macrophage ìƒì¡´ ì—°ì¥

Protein synthesis:
  - Lgt1, Lgt2, Lgt3 (Glucosyltransferase)
  - Translation elongation factor ë³€í˜•
```

---

## ğŸ’¡ ì˜ˆìƒ ì§ˆë¬¸ ë° í† ë¡  í¬ì¸íŠ¸

### ë°œí‘œ ì¤‘/í›„ ë¬¼ì–´ë³¼ ì§ˆë¬¸ë“¤

**1. Effector ë°œí˜„ ì‹œê¸° ì¡°ì ˆ**:
> "SidE, LnaB, MavLì€ ê°ì—¼ ê³¼ì •ì—ì„œ ì–¸ì œ ì–´ë–»ê²Œ ë°œí˜„ ì¡°ì ˆë˜ë‚˜ìš”? Temporal regulationì´ ìˆë‚˜ìš”?"

**ë°°ê²½**: Ubiquitin homeostasisë¥¼ ìœ„í•´ì„œëŠ” ì‹œê°„ì°¨ ë°œí˜„ì´ ì¤‘ìš”í•  ê²ƒ

**2. ë‹¤ë¥¸ ì„¸í¬ ë‚´ ê¸°ìƒ ì„¸ê· ê³¼ì˜ ë¹„êµ**:
> "Salmonella, Shigella ë“± ë‹¤ë¥¸ intracellular bacteriaë„ ìœ ì‚¬í•œ Ub manipulationì„ í•˜ë‚˜ìš”?"

**ë°°ê²½**: Legionellaì˜ PR-Ub ì‹œìŠ¤í…œì´ ë…íŠ¹í•œì§€ ê¶ê¸ˆ

**3. Macrophage vs. Amoeba**:
> "Amoebaì™€ mammalian macrophageì—ì„œ ì´ ì‹œìŠ¤í…œì˜ íš¨ìœ¨ì´ ë‹¤ë¥¸ê°€ìš”?"

**ë°°ê²½**: LegionellaëŠ” ì›ë˜ amoeba parasite

**4. ì¹˜ë£Œì œ ê°œë°œ ì „ë§**:
> "SdeA inhibitor screening assay ê°œë°œ í›„ ìœ ë§í•œ hit compoundê°€ ë‚˜ì™”ë‚˜ìš”?"

**ë°°ê²½**: 2025 ChemBioChem ë…¼ë¬¸ í›„ì† ì—°êµ¬

**5. MavL knockout íš¨ê³¼**:
> "MavL ê²°ì† mutantëŠ” infection phenotypeì´ ì–´ë–¤ê°€ìš”? Ub poolì´ ê³ ê°ˆë˜ë‚˜ìš”?"

**ë°°ê²½**: Homeostasisì˜ ì¤‘ìš”ì„± ê²€ì¦

---

## ğŸ“š ì¶”ì²œ ì‚¬ì „ í•™ìŠµ ìë£Œ

### í•„ìˆ˜ ë…¼ë¬¸ (ì‹œê°„ ìˆìœ¼ë©´ Abstractë§Œì´ë¼ë„!)

**1. ìµœì‹  ì—°êµ¬ (2024)**:
```
1) Nature Communications, July 2024
   "Legionella maintains host cell ubiquitin homeostasis..."
   â†’ ì „ì²´ ì‹œìŠ¤í…œ ì´í•´ (SidE-LnaB-MavL)

2) Nature Communications, March 2024
   "Legionella metaeffector MavL reverses ubiquitin ADP-ribosylation..."
   â†’ MavL ë©”ì»¤ë‹ˆì¦˜ ìƒì„¸
```

**2. SidE ë°œê²¬ ë…¼ë¬¸ë“¤**:
```
3) Qiu et al., Nature 2016
   "Ubiquitination independent of E1 and E2 enzymes by bacterial effectors"
   â†’ SidE ìµœì´ˆ ë°œê²¬!

4) Bhogaraju et al., Nature 2016
   "Phosphoribosylation of Ubiquitin..."
   â†’ PR-Ub êµ¬ì¡° ê·œëª…
```

### í•µì‹¬ ê°œë… ë³µìŠµ

**ë°˜ë“œì‹œ ì•Œì•„ì•¼ í•  ìš©ì–´**:
- **PR-Ub** (phosphoribosyl-ubiquitin): SidEê°€ ë§Œë“œëŠ” ë³€í˜• Ub
- **ADP-ribosylated Ub**: LnaBê°€ ë§Œë“œëŠ” ì¤‘ê°„ì²´
- **Metaeffector**: ë‹¤ë¥¸ effectorë¥¼ ì¡°ì ˆí•˜ëŠ” effector (MavL)
- **Macrodomain**: ADP-ribose ê²°í•©/ì œê±° domain
- **LCV** (Legionella-containing vacuole): Legionellaì˜ ì§‘

**ë¹„êµ ì´í•´**:
```
ì¼ë°˜ Ubiquitination:
  E1 â†’ E2 â†’ E3 â†’ Substrate-Ub (Lys)

SidE Ubiquitination:
  SidE â†’ PR-Ub â†’ Substrate-PR-Ub (Ser)
       â†’ LnaB â†’ ADP-ribosyl-Ub
       â†’ MavL â†’ Ub ì¬ìƒ
```

---

## ğŸŒŸ ì´ ë°œí‘œì˜ í•˜ì´ë¼ì´íŠ¸

### Take-home Messages

**1. ì„¸ê· ì˜ ì°½ì˜ì„±**:
- E1/E2/E3 ì—†ì´ë„ ubiquitination ê°€ëŠ¥!
- ì§„í™”ì ìœ¼ë¡œ ë…ë¦½ì  ë©”ì»¤ë‹ˆì¦˜ ë°œëª…

**2. ê· í˜•ì˜ ì¤‘ìš”ì„±**:
- Host manipulationê³¼ host survivalì˜ trade-off
- Effector cascadeë¥¼ í†µí•œ ì •êµí•œ ì¡°ì ˆ

**3. ì¹˜ë£Œì œ íƒ€ê²Ÿ**:
- ë…íŠ¹í•œ ë©”ì»¤ë‹ˆì¦˜ â†’ selective inhibition ê°€ëŠ¥
- Multi-target approach ê³ ë ¤ í•„ìš”

**4. ë°©ë²•ë¡ ì  í˜ì‹ **:
- Macrodomainì˜ ìƒˆë¡œìš´ ê¸°ëŠ¥ ë°œê²¬
- ADP-ribosylation biologyì˜ í™•ì¥

### ë„¤íŠ¸ì›Œí‚¹ í¬ì¸íŠ¸

**Luo êµìˆ˜ì™€ ëŒ€í™” ì‹œ ì–¸ê¸‰í•˜ë©´ ì¢‹ì„ ì£¼ì œ**:
- "2024ë…„ Nature Comm. 2í¸ ì¶•í•˜ë“œë¦½ë‹ˆë‹¤!"
- "MavLì˜ arginine specificityê°€ ì¸ìƒ ê¹Šì—ˆìŠµë‹ˆë‹¤"
- "SdeA inhibitor screening í›„ì† ì—°êµ¬ê°€ ê¶ê¸ˆí•©ë‹ˆë‹¤"
- "Ub homeostasis ê°œë…ì´ ë‹¤ë¥¸ ë³‘ì›ì„± ì„¸ê· ì—ë„ ì ìš©ë ê¹Œìš”?"

**ê´€ë ¨ ì„¸ì…˜ ì—°ê³„**:
- **S1 (Bacterial Pathogenesis)**: Tao Dong (T6SS, Phase separation)
- **S8 (Diagnosis and Treatment)**: AMR, novel therapeutics

---

## ğŸ“Š ë°œí‘œ í‰ê°€ ê¸°ì¤€

### ìš°ì„ ìˆœìœ„: â­â­â­â­â­ (95/100)

**ì°¸ì„ ì´ìœ **:
```
âœ… Plenary Lecture (ìµœê³  ë“±ê¸‰)
âœ… ì„¸ê³„ì  ê¶Œìœ„ì (2025 Award ìˆ˜ìƒ)
âœ… ìµœì‹  ì—°êµ¬ (2024 Nature Comm. x2)
âœ… ë…íŠ¹í•œ ë©”ì»¤ë‹ˆì¦˜ (êµê³¼ì„œì  ê°€ì¹˜)
âœ… ëª¨ë“  ë¯¸ìƒë¬¼í•™ìì—ê²Œ ìœ ìµ
```

**ëˆ„ê°€ ë“¤ì–´ì•¼ í•˜ë‚˜**:
- âœ… **ì„¸ê·  ë³‘ì›ì„±** ì—°êµ¬ì (í•„ìˆ˜!)
- âœ… **PTM** (post-translational modification) ì—°êµ¬ì
- âœ… **ìˆ™ì£¼-ë³‘ì›ì²´ ìƒí˜¸ì‘ìš©** ì—°êµ¬ì
- âœ… **ì„¸í¬ ìƒë¬¼í•™** ì—°êµ¬ì
- âœ… **êµ¬ì¡° ìƒë¬¼í•™** ì—°êµ¬ì (Macrodomain)
- âœ… **ì‹ ì•½ ê°œë°œ** ì—°êµ¬ì

**ì£¼ì˜ì‚¬í•­**:
- 40ë¶„ ë°œí‘œ â†’ ê¹Šì´ ìˆëŠ” ë‚´ìš© ì˜ˆìƒ
- ìƒí™”í•™/êµ¬ì¡° ìƒë¬¼í•™ ë°°ê²½ ìˆìœ¼ë©´ ë” ìœ ìµ
- ì§ˆì˜ì‘ë‹µ ì‹œê°„ì— ì ê·¹ ì°¸ì—¬ ì¶”ì²œ!

---

**ì‘ì„±ì¼**: 2025-10-26
**ì‘ì„±ì**: Conference Advisor (MSK2025 ì¤€ë¹„íŒ€)
**ì°¸ê³  ë¬¸í—Œ**: Nature Communications 2024 (March, July), ChemBioChem 2025
